Lineage Cell Therapeutics Receivables

The latest receivables for LCTX is $810K as of March 2026. That compares with $210K in the prior-year period — up 278.4% year over year. Investors often review this figure alongside Lineage Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, LCTX's receivables moved from $210K to $810K — a 278.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lineage Cell Therapeutics's operating scale or balance-sheet position.

A receivables figure of $810K for LCTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LCTX's receivables ($810K), review year-over-year change from $210K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lineage Cell Therapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.